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Purpose	Genetic information has health implications for patients and their biological relatives. Death of a
patient before sharing a genetic diagnosis with at-risk relatives is a missed opportunity to provide
important information that could guide interventions to minimize cancer-related morbidity and mortality
in relatives.
Methods	We performed semi-structured interviews with individuals diagnosed with Lynch syndrome at 1 of
4 health systems to explore their perspectives on whether health systems should share genetic
risk information with relatives following a patient’s death. An inductive, open-coding approach was
used to analyze audio-recorded content, with software-generated code reports undergoing iterative
comparative analysis by a qualitative research team to identify broad themes and representative
participant quotes.
Results 	Among 23 participating interviewees, 19 supported health systems informing relatives about their
Lynch syndrome risk while the remaining 4 were conflicted about patient privacy. Most (n=22) wanted
their Lynch syndrome diagnosis shared with relatives if they were unable to share and to be informed
of their own risk if a diagnosed relative was unable to share. The most common issues noted regarding
information-sharing with relatives included patient privacy and privacy laws (n=8), potential anxiety
(n=5), and lack of contact information for relatives (n=3). Interviewee perspectives on how health
systems could communicate genetic findings generated a consensus: When — a few months after but
within a year of the patient’s death; How — explanatory letter and follow-up phone call; and Who — a
knowledgeable professional.
Conclusions	Interviews demonstrated strong and consistent perspectives from individuals diagnosed with Lynch
syndrome that health systems have a role and responsibility to inform relatives of genetic findings
following a patient’s death. (J Patient Cent Res Rev. 2022;9:282-289.)
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having Lynch syndrome. Thus, cascade screening, a
process to identify additional relatives who may have
Lynch syndrome, provides the opportunity for relatives
to learn about their own cancer risk.
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Current cascade screening approaches rely on patients
to contact their at-risk relatives and inform them of
their potential genetic risk and opportunity for genetic
counseling and testing. However, situations where the
patient dies before receiving or sharing genetic testing
results represent a missed opportunity for relatives to
receive important information that could guide decisionmaking around learning their own genetic risk and

enetic information is relevant not only to
patients who undergo genetic testing; it also has
implications for their biological relatives. In the
case of Lynch syndrome, a hereditary cancer syndrome
with an increased risk of colorectal and endometrial
cancers,1-5 first-degree relatives are at 50% risk of also
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potentially taking medical actions to mitigate morbidity
and mortality. Such a scenario is particularly relevant in
the context of genetic testing initiated following a cancer
diagnosis when patients are at elevated risk for cancerrelated death. Without consistent practices to capture
patient preferences for sharing genetic information with
relatives in the event of death, health systems are faced
with legal and ethical challenges on whether to contact
relatives to share the genetic information. When a
specific patient’s preferences are unknown, perspectives
of patients in general may help guide policies around
disclosure to relatives.
There has been exploration of this challenge in the
research setting, with support for sharing genetic findings
associated with significant health outcomes for which
there are actions relatives could take to ameliorate
outcomes,6-9 including specific guidance that disclosure
should be active and directly disclosed to all relatives
after the death of a patient.8 Directly contacting relatives
to inform them of their potential genetic risk following
the death of a patient has been described as “morally
justifiable” for significant and actionable genetic
findings.10 Though empirical evidence is limited, a few
studies to date have administered direct assessments of
patient perspectives regarding result disclosure to atrisk relatives after death.11-13 In one study, the majority
(92%) of 78 adults enrolled in a research study to receive
genomic sequencing for hereditary cancer provided
permission to have their results returned to a relative
in the event of their death when offered this option.11
Further, in a recent update of survey results among 464
patients in a pancreatic cancer biobank14 (12.3% of which
had received genetic counseling), only 4% indicated
they would want their genetic results kept private after
their death.12 Lastly, in a survey of 555 participants of
the OurGenes biobank, only 9% indicated they would
not want their research results disclosed to a biological
relative after their death.13 Although these studies provide
valuable insight into patient perspectives in a pre-genetic
testing context, additional evidence is needed regarding
preferences, concerns, and motivations, particularly
among patients who have already received a genetic
diagnosis that has health implications for relatives.
In this study, we explored perspectives of individuals
diagnosed with Lynch syndrome as part of the
Implementing Universal Lynch Syndrome Screening
(IMPULSS) project.15 We obtained patient perspectives
on health systems sharing the genetic diagnosis of Lynch
syndrome of a deceased patient with relatives. This study
aims to find novel insights that can shape clearer guidance
for developing relevant policies and procedures.
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METHODS

Recruitment

Participants for this substudy were recruited as part
of the larger IMPULSS study aimed at facilitating
implementation of universal screening for Lynch
syndrome across health systems.15 Patients diagnosed
with Lynch syndrome as part of that Lynch syndrome
screening program were identified across 4 health systems:
Kaiser Permanente Northwest (KPNW), Geisinger,
HealthPartners, and Palo Alto Medical Foundation
(PAMF). Identification of patients for this substudy
included searches of electronic medical records with
relevant clinical codes, institutional tumor registries, and
genetic test results with chart reviews to confirm eligibility.
Research staff from each health system mailed
recruitment letters to eligible patients at their site
describing the study and providing the opportunity
to opt in or out of participation. Contact information
of patients who had opted in (patients at PAMF were
required to opt in for study participation) or had not opted
out (KPNW, Geisinger, HealthPartners) of participation
was provided to the KPNW qualitative research team
(J.L.S., A.J.F., J.V.D.) via International Organization for
Standardization (ISO)-approved secure data transfer.
The KPNW qualitative research team followed up with
potential participants by telephone.
Data Collection

The qualitative team worked closely with research staff from
participating health systems to develop an in-depth semistructured interview guide to capture patient perspectives
of universal Lynch syndrome screening among patients
with Lynch syndrome. A patient advocate with an inherited
colorectal cancer syndrome also reviewed and provided
feedback on the interview guide. The analyses described
herein focused on responses to a set of questions around
sharing Lynch syndrome diagnosis information with
relatives following the death of a patient.
Interviews were conducted via telephone, lasted
approximately 60 minutes, and were audio-recorded.
Interviewees provided verbal consent before the
interview and received a $25 gift card for participation.
All interviews were conducted and analyzed by research
staff trained in qualitative methods (J.L.S., A.J.F., J.V.D.).
Interview procedures and materials received human
subjects research approval from multiple institutional
review boards (ie, Geisinger and PAMF).
Data Analysis

Interview recordings were transcribed verbatim to
facilitate content analysis. An inductive, open-coding
approach was employed.16,17 First, an initial coding
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scheme was developed by the qualitative team (J.L.S,
A.J.F, J.V.D.) based on multiple reviews of a subsample
of 6 transcripts. Then, the preliminary coding scheme
was shared with the larger study team for feedback and
refinement. Next, the final coding scheme was applied to the
remaining transcripts. The qualitative team met regularly
to discuss coding and any ongoing refinements. Coding
was conducted using qualitative software (NVivo 12,
QSR International).
Code reports were reviewed multiple times by the
whole qualitative team utilizing a constant comparative
analysis approach to interpret and summarize data and
identify broad themes.17-19 Preliminary theme reports
were shared with the larger study team for feedback. The
qualitative team reviewed transcripts and responded to
feedback and questions regarding interpretation of data
in the theme reports. This iterative process led to a final
set of findings and representative participant quotes
presented in this manuscript.

RESULTS

Study Participants

A total of 44 patients were recruited by the KPNW
qualitative team to participate in an interview: 5
declined, 1 was ineligible (hard of hearing), 15 were
never reached, and 23 interviews were completed.
Participant characteristics are shown in Table 1. Although
the target population was individuals diagnosed with
Lynch syndrome through a Lynch syndrome screening
program, during interviews we discovered 6 participants
were diagnosed during cascade screening following the
diagnosis of a relative. Given their perspectives still
inform sharing of genetic information among relatives,
interview responses from these participants were included
in this analysis.
Perspectives on the Health System’s Role in
Sharing Lynch Syndrome Diagnosis Information
With Relatives Following the Death of a Patient

Participants were asked what a health system should do
if a person with a genetic diagnosis of Lynch syndrome
dies prior to relatives being informed about the diagnosis
and their subsequent risk of also having Lynch syndrome
(Table 2). Most (19 of 23) had the initial reaction that the
health system had a responsibility to inform relatives. The
remaining participants (4 of 23) did not clearly endorse
informing the family in their initial reaction; they felt
conflicted and could see that although it was important to
share the information, it was also important to protect the
patient’s privacy.
During interviews, it became clear how the interviewees’
personal experiences shaped their perspectives. Some

284 JPCRR • Volume 9, Issue 4 • Fall 2022

Table 1. Participant Descriptive Characteristics
Characteristic
Age in years, mean (range)

N=23
60 (33–84)

Gender, n
Female
Male

14
9

Patient-reported race/ethnicity, n
White
White and American Indian
White and Jewish
Hispanic
Asian

19
1
1
1
1

Household income, n
<$15,000
$15,000–$30,000
$30,000–$50,000
$50,000–$75,000
$75,000–$100,000
$100,000–$150,000
$150,000–$200,000
Prefer not to answer

3
4
4
3
4
2
2
1

Highest level of education, n
High school
Trade school
Some college
College graduate

6
5
3
9

Married or living with partner, n
No
Yes

10
13

Family members receiving care from
same health system, n
None
Child(ren)
Sibling(s)
Child(ren) and Sibling(s)
Child(ren) and Grandchild(ren)

15
5
1
1
1

Health system, n
Kaiser Permanente Northwest
Geisinger
HealthPartners
Palo Alto Medical Foundation

3
8
9
3

participants expressed that their own diagnoses of
cancer made them wish they had known their diagnosis
of Lynch syndrome earlier, potentially shaping their
perspectives supporting relatives’ access to genetic
cancer risk information. One participant noted that
being adopted and not having any family health history
made them feel strongly about learning about family
genetic risk information.

Original Research

Table 2. Participant Perspectives on the Health System’s Role in Sharing Lynch Syndrome Diagnosis
Information With Relatives Following the Death of a Patient
Interview prompt: Because family members of an individual with Lynch syndrome are at risk and can benefit from early
prevention and screening options, we’d like your thoughts on a sensitive topic about what to do if the person confirmed
with Lynch syndrome has died and their family members have not been told about the possibility that they may also have
Lynch syndrome. This is a challenging question because federal laws and regulations protect the privacy of a person’s
health information, even after that person has died. Yet others believe that health information like this should be shared if
it could benefit others, including relatives. We’ve been talking [earlier in interview] about the value in learning about Lynch
syndrome in terms of the knowledge for yourself and for your relatives. But there are ongoing questions about whether
a health system should protect a person’s privacy and health information after death versus the responsibility to tell that
person’s family members about the Lynch syndrome diagnosis since it can impact their health. Based on what I just
explained, what is your reaction to this challenge and the information I just shared?
Key findings

Example quotes

Most participants (19 of 23) had the initial
reaction that family should be informed,
and it is OK to share the Lynch syndrome
diagnosis with family members after a
patient’s death.

“I know that there are all these privacy issues, but if the person passes away
and there is [sic] family members that should know that they may be at risk, I
think after the passing away that the family members should be informed.”

After their initial reaction, some (4 of 19)
believed that the family should be informed,
reflecting that the situation is complicated
and that although it is important to inform
the family, they also see concerns about
patient privacy.

“I just believe that the doctor/patient privilege should be waived in situations
like that.”
“I think that information should be made available to the family so they could
keep an eye on it [cancer] so it doesn’t get anybody else in the family.”
“It’s a hard thing. … You want them to have the best options moving forward.
But it’s also a privacy thing.”

4 of 23 participants did not clearly endorse “It's not hurting the person who died. And that information would almost
informing the family in their initial reaction
certainly benefit any of their survivors. … But I don’t know. It’s a tough call.
because they felt like they could “see it
You want to respect peoples’ privacy and things like that.”
both ways” regarding sharing the result with
family members versus patient privacy.

Health System Sharing of a Lynch Syndrome
Diagnosis From the Perspective of a Patient With
Lynch Syndrome and of a Relative

When asked if they would want the health system to
inform their relatives about their diagnosis of Lynch
syndrome if they became deceased before being able
to share this information, most (22 of 23) responded
that they would want the health system to inform their
relatives. General reasons included that it would give their
relatives important information they could act on to avoid
cancer or catch it at an early stage and that sharing the
information would not “hurt” the person who is deceased.
Participants were then asked about a hypothetical
scenario: one of their relatives had been diagnosed with
Lynch syndrome but had died before sharing the diagnosis
with the participant and other relatives (Table 3). Most
(22 of 23) stated they would want the health system to
inform them of their Lynch syndrome risk. General
reactions included the belief that they “have a right to
know” so they could act on the information and learn
about their own diagnosis of Lynch syndrome. They felt
this information was important for early cancer detection
and general family health history knowledge.

Original Research

One participant did not want the health system to share
any diagnosis information or be informed of the diagnosis
of Lynch syndrome of a relative, while generally agreeing
that sharing this information with relatives is important
(Table 3). However, the participant worried about the
“slippery slope” of this potential breach in privacy and
how it could facilitate additional privacy breaches in the
future that the participant may not be so comfortable
with. The participant also expressed concern about how
the disclosure may impact insurance and employment of
those relatives.
Concerns About Health Systems Informing
Relatives of a Diagnosis of Lynch Syndrome in a
Patient Who Is Deceased

During interviews, 9 of 23 expressed they had “no
concerns” around health systems sharing genetic
information with relatives (Table 4). The remaining
participants (14 of 23) expressed 1 or more concerns.
Eight participants noted 1 or more issues or concerns
around protecting privacy or changing the current privacy
laws; 3 participants clearly felt the benefit of sharing
genetic information was more important than privacy but
that health systems or lawmakers need to generate clear
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Table 3. Patient Perspectives on the Health System Sharing a Lynch Syndrome Diagnosis From the
Perspective of a Patient With Lynch Syndrome and of a Relative
Interview prompt: If you were confirmed to have Lynch syndrome but were deceased before being able to inform family
members, would you want your health system to inform them of the possible hereditary risk? Why or why not?
Key findings

Example quotes

22 of 23 participants endorsed that the
health system should share their own
personal Lynch syndrome diagnosis with
relatives.

“Share away. Who cares, I’m dead. It doesn’t matter.”
“For me it’s a no brainer to tell my family.”

1 of 23 participants agreed in general
that sharing this information is important
but had concerns about privacy issues,
particularly around it being a “slippery
slope” in sharing private information.

“But where does it stop, right? So today it’s the hospitals, the government, the
insurance companies, whoever have the right to tell and then the obligation to
tell the children about Lynch syndrome. Tomorrow, what else will they want to
tell the children that maybe I wouldn’t agree with? ... It’s an ethical dilemma,
and by the same token, it's a slippery slope.”

“My personal view is that if doctors are aware of this particular syndrome,
whether I’m alive or not should not affect them that they pass the information
on, at least to my wife or to my next of kin so that they can share it with
whoever they think appropriate.”

Interview prompt: If a blood relative, such as a sibling, was confirmed to have Lynch syndrome but became deceased
before being able to share with you and other family members, would you want the health system to inform you of this
possible hereditary risk? Why or why not?
Key findings

Example quotes

22 of 23 participants noted that the health “I think it is our right to know. And then that would be our decision [to take
system should share the Lynch syndrome action]. But we should be advised whether we are at risk or we are not.”
diagnosis so that family members would
learn their own potential risk.
“Of course, I would want to know that, and I would be mad that I didn’t know it!”
“Yes – being adopted like I am, and knowing no medical history in the family, I
think all medical history should be available to the family, period”
1 of 23 participants agreed in general
that sharing the information is important
but worried about patient privacy and
potential insurance or employment issues
of the relatives.

“Not because of the Lynch syndrome but because of what the next step and the
next step and the next step are… I don’t think they [health system] should do it,
I don’t want to tell them how to do it. I guess my big concerns with something
like that is twofold – is telling insurance companies if we ever got into a climate
where you could raise rates on somebody who was more likely to get sick.
So that would be the first concern that I would have. The second concern
that I would have would be employers … so the company I work for … has a
company-funded health care program. So if they know that I’m likely to have
cancer, is that going to color their actions whether it be for hiring or if there’s
layoffs, who goes?”

guidelines around exactly who the information could be
shared with (eg, first-degree relatives); and 3 participants
specifically noted that changes in privacy laws would be
needed for health systems to share genetic information.
Three participants stated that they recognized the tension
between sharing genetic information and protecting
patient privacy and the need for more thought, but had no
clear guidance on a solution.
Additional issues were noted beyond privacy. For
instance, 4 participants noted negative reactions (eg,
fear, not being able to “handle” the information, not
wanting the information) following being informed
about the diagnosis of Lynch syndrome in their relatives;
3 participants noted logistical challenges around lack
of or outdated contact information for relatives; and
2 participants expressed concern that the relatives’
286 JPCRR • Volume 9, Issue 4 • Fall 2022

insurance rates might increase if it was known there was
a diagnosis of Lynch syndrome in the family. Lastly, 1
participant noted there might be relatives the patient was
not in contact with by choice and the patient may not
have chosen to share the diagnosis of Lynch syndrome
with these relatives.
Perspectives on How Lynch Syndrome Diagnosis
Information Should Be Provided to Relatives
Following a Patient’s Death

Participants were asked to provide guidance to health
systems on how to inform relatives of the diagnosis of
Lynch syndrome of a deceased patient (Table 5). Of the 17
participants asked about timing of contact, 16 suggested
health systems should wait a few months after the patient’s
death to allow for mourning but should reach out within the
year. One participant suggested the health system should
Original Research

Table 4. Expressed Benefits and Concerns About Health Systems Sharing Lynch Syndrome Diagnosis
Information Following a Patient’s Death (may have endorsed more than 1 benefit or concern)
BENEFITS
Key findings

Example quotes

Family members have a “right to know”
(n=12)

“For my descendants that could be affected by this, if they were prevented from
getting the preventative screenings that could possibly save their life and they
didn’t get it because of that privacy thing, that would be wrong. That would be
Important health information and potential simply wrong.”
cancer prevention (n=9)
“Essentially that person has died. And so the risk is for all the survivors and not
Information is knowledge (n=6)
for the dead. So, if that information can help ease the pain, or ease the worry or
eliminate the risk, I’m not sure we should avoid that responsibility, you know.”
“Give them [family] as much information as possible so that they can decide
what to do next.”
CONCERNS
Key findings

Example quotes

No concerns (n=9)

“I personally have no barriers or concerns … [family members] should know and
if they want to ignore the situation, then that’s totally in their court.”

Concerns (n=14) regarding:
o Privacy and privacy laws (n=8)
o May create anxiety or upset family
members (n=5)
o No contact information or information
not up to date (n=3)
o Increase family members’ insurance
rates (n=2)
o Family members not on speaking
terms (n=1)

“The law would have to be changed where, if somebody has had a genetic
mutation, they can have the immediate family know about it or be aware of it.
But I guess the laws would have to change first. I know they’re not going to risk
being sued and everything for release of information they can’t release.”
"It could be a scary thing sometimes for someone that you might send it to. I
mean, are they emotionally capable of handling it? It might be pretty hard to
know.”
“The health care provider, or whoever diagnosed this, is not going to contact a
family member if they don’t know where to contact them.”
I guess the other dilemma is if like their insurer found out – it's possible they
could raise their insurance rates or something like that.”

reach out “as soon as possible.” All 22 participants who
were asked about how the health system should contact
relatives suggested there should be a personalized outreach
and the opportunity to speak to someone knowledgeable
about Lynch syndrome. The consensus was this approach
could be two-pronged: a letter followed by a face-to-face
appointment or phone call.
In all, 9 participants noted health systems should consider
implementing protocols to obtain permission from the
patient at the time of genetic testing on whether or not
to communicate the genetic findings with relatives in the
event of their death. Suggestions for implementing this
process to capture when patients were willing for their
results to be shared included signing a consent or written
waiver regarding permission to share and a flag in the
electronic medical record noting the patient would like
their genetic findings shared with relatives.

DISCUSSION

Overall, the qualitative results in this study demonstrate
strong and consistent perspectives from individuals with
Original Research

a diagnosis of Lynch syndrome that health systems have
a role and responsibility to inform relatives of genetic
findings following the death of a patient. Consensus was
that this information is important for relatives to receive
given it has significant implications for their future health
and well-being. Importantly, roughly 35% of participants
had at least one first-degree relative who also receives
care from the same health system, emphasizing the
potential impact that sharing this information could have
on patient care.
The most common issues noted by interviewees were
centered around patient privacy, an important concern
in cases where patient preferences around sharing their
genetic information were not captured prior to death.
Thus, health systems need to balance the privacy of
the deceased patient with the opportunity to minimize
health risks in relatives by providing them with important
cancer risk information. This barrier could be addressed
prospectively by systematically capturing preferences
of patients, including who they want the information
shared with and their contact information, consistent
aah.org/jpcrr
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Table 5. Perspectives on How Lynch Syndrome Diagnosis Information Should Be Provided to Relatives
Following a Patient’s Death
Key findings

Example quotes

When the information should be shared: “Hopefully it wouldn’t be too long after the person passed away – like it wouldn’t
A few months after, but within a year
be over a year but within a years’ time.”
How the information should be shared:
Explanatory letter and follow-up phone
call with an option to meet face to face

“A letter … give them the facts … and explain why you need to come in and
speak to someone.”

Who should share the information:
Health professional knowledgeable
about Lynch syndrome

“I would like to be informed by a professional or someone who had information
that could answer some of my questions … I would like to have a voice to talk to.”

with current guidance in the research setting.10,20 A
single representative for the family could be chosen to
disseminate findings across relatives. However, there
may be limitations to this approach. First, this person
may be a spouse or partner who is not biologically related
to the patient and thus will not directly benefit from
receiving the information. Second, this person will act as
“gatekeeper” of the information and may not share with
all relatives who may have similar genetic risk.

their biospecimen be shared after death. The results of
our study are consistent with these previous findings and
provide important perspectives from patients who have
a genetic finding that relatives can act on to improve
their own health outcomes. Interview findings indicated
that hesitancy to share may arise from concerns about
how their genetic information may be used beyond this
context (ie, a “slippery slope” regarding patient privacy).

Prior studies of patient perspectives on sharing genetic
findings with relatives while the patient is still living
indicate that patients support disclosure of findings to
relatives and that relatives want to be provided with
information that may be important to their health.12,21,22
Findings from qualitative interviews with 33 patients
seen in a genetics clinic for hereditary cancers and cardiac
conditions (29 of whom had received genetic testing with
a positive finding, 2 a negative finding, and 2 no testing)
indicated two emerging themes when participants were
asked about their perspectives on confidentiality and
consent around disclosure of their genetic findings to
their relatives: 1) Patients viewed genetic information as
familial and thus family members had a right to know
their genetic risk; and 2) Participants had concerns about
what implications there would be from their genetic
testing information being treated as familial and wanted
to ensure they would be informed about how their genetic
information would be shared.21 Shifting to the context
of disclosure of a patient’s genetic information with
relatives after death, the empirical evidence is limited
to quantitative studies of patient perspectives among
research participants. Results of three studies showed
the majority support such sharing; one study reported
that 92% support providing permission for their research
genomic sequencing results to be returned to a relative
in the event of their death,11 and two studies of surveyed
biobank participants indicated that 96%12 and 91%,13
respectively, support having any genetic test results from

It is important to recognize that perspectives presented in
this study are limited to individuals who received a genetic
diagnosis of Lynch syndrome, thus, their perspectives may
differ from their relatives. Future studies should focus on
capturing perspectives of relatives to explore their interest
in receiving information, with a focus on relatives’ right
to not know this information.10 Additionally, although
we took many steps to ensure our data were grounded
in patient perspective (eg, consistent use of a formal
interview guide, trained interviewers, formal coding/
analysis) and recruited individuals from health systems
in different geographic regions, it is possible we did not
capture a full range of patient perspectives. Thus, future
studies should aim to capture patient perspectives across
a diverse range of patient populations, including patients
from different racial, ethnic, and cultural backgrounds.
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Limitations

CONCLUSIONS

Findings provided the novel insight from patients with
Lynch syndrome that health systems have a role and
responsibility to share genetic information with relatives
following a patient’s death. These findings could be
leveraged to guide future health system policies and
protocols in this context. Further, patients’ perspectives
can be extrapolated to other genetic conditions and risk
variants, with options for medical intervention that may
occur in the clinical or research contexts, including in the
context of the biobank setting wherein biospecimens may
be analyzed and future genetic variants identified.

Original Research

Patient-Friendly Recap
•P
 atients are diagnosed with Lynch syndrome
through genetic testing, results that, if shared, could
lead to earlier diagnosis in at-risk relatives.
•B
 ecause those with Lynch syndrome may die prior
to contacting relatives themselves, study authors
interviewed patients to learn their attitudes toward
whether health systems should share this genetic
information after their death.
•W
 hile most interviewees supported data sharing
with relatives after the death of the patient, some
expressed concerns over privacy and the possibility
that their relatives might prefer not to know.
•S
 uggestions for engaging relatives included doing
so first via letter with phone follow-up by a health
professional knowledgeable in Lynch syndrome.
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